Press releases

Feb 14, 2007 / Product

Actavis Launches Alprazolam ER Tablets in the U.S.

Actavis today announced that it has received approval from the U.S. Food & Drug Administration to market Alprazolam ER tablets. Distribution of the product will commence in coming weeks.

Alprazolam ER tablets, the generic equivalent of Pfizer’s Xanax® XR tablets, will be available in 0.5 mg, 1 mg, 2 mg, and 3 mg strengths. Alprazolam ER tablets are indicated for the treatment of anxiety and panic disorder.

Annual sales of Alprazolam ER tablets in the U.S. were approximately US$53.9 million for the twelve months ending December 2006 according to IMS Health data.